| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CIP2A |
| Uniprot No | Q8TCG1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-905aa |
| 氨基酸序列 | MDSTACLKSLLLTVSQYKAVKSEANATQLLRHLEVISGQKLTRLFTSNQILTSECLSCLVELLEDPNISASLILSIIGLLSQLAVDIETRDCLQNTYNLNSVLAGVVCRSSHTDSVFLQCIQLLQKLTYNVKIFYSGANIDELITFLIDHIQSSEDELKMPCLGLLANLCRHNLSVQTHIKTLSNVKSFYRTLITLLAHSSLTVVVFALSILSSLTLNEEVGEKLFHARNIHQTFQLIFNILINGDGTLTRKYSVDLLMDLLKNPKIADYLTRYEHFSSCLHQVLGLLNGKDPDSSSKVLELLLAFCSVTQLRHMLTQMMFEQSPPGSATLGSHTKCLEPTVALLRWLSQPLDGSENCSVLALELFKEIFEDVIDAANCSSADRFVTLLLPTILDQLQFTEQNLDEALTRKKCERIAKAIEVLLTLCGDDTLKMHIAKILTTVKCTTLIEQQFTYGKIDLGFGTKVADSELCKLAADVILKTLDLINKLKPLVPGMEVSFYKILQDPRLITPLAFALTSDNREQVQSGLRILLEAAPLPDFPALVLGESIAANNAYRQQETEHIPRKMPWQSSNHSFPTSIKCLTPHLKDGVPGLNIEELIEKLQSGMVVKDQICDVRISDIMDVYEMKLSTLASKESRLQDLLETKALALAQADRLIAQHRCQRTQAETEARTLASMLREVERKNEELSVLLKAQQVESERAQSDIEHLFQHNRKLESVAEEHEILTKSYMELLQRNESTEKKNKDLQITCDSLNKQIETVKKLNESLKEQNEKSIAQLIEKEEQRKEVQNQLVDREHKLANLHQKTKVQEEKIKTLQKEREDKEETIDILRKELSRTEQIRKELSIKASSLEVQKAQLEGRLEEKESLVKLQQEELNKHSHMIAMIHSLSGGKINPETVNLSI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CIP2A重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*CIP2A modulates cell cycle progression in human cancer cells by regulating the stability and activity of Plk1*
**作者**：Khanna A, et al.
**摘要**：研究利用重组CIP2A蛋白与Plk1激酶体外共孵育实验，揭示CIP2A通过抑制PP2A磷酸酶活性，稳定Plk1蛋白并促进其激酶活性，从而驱动肿瘤细胞周期进程。
2. **文献名称**：*Structural basis for CIP2A-mediated inhibition of PP2A in cancer signaling*
**作者**：Li W, et al.
**摘要**：通过大肠杆菌表达并纯化重组CIP2A蛋白，结合冷冻电镜技术解析CIP2A-PP2A复合物结构，阐明CIP2A通过特定结构域竞争性抑制PP2A对Akt的去磷酸化作用，促进肿瘤存活。
3. **文献名称**：*Development of a monoclonal antibody targeting CIP2A using recombinant protein immunization*
**作者**：Zhang Y, et al.
**摘要**：利用昆虫细胞表达系统制备重组人CIP2A蛋白，并以此为抗原开发高特异性单克隆抗体，验证其在乳腺癌组织中的诊断应用潜力。
(注：上述文献为示例，实际引用时建议通过PubMed或Google Scholar以“CIP2A recombinant protein”为关键词检索近年研究。)
CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) is a human oncoprotein that has gained attention for its role in cancer progression and therapeutic resistance. Initially identified as a binding partner of Protein Phosphatase 2A (PP2A), CIP2A functions as an endogenous inhibitor of PP2A, a tumor-suppressive phosphatase involved in cell cycle regulation, apoptosis, and signal transduction. By suppressing PP2A activity, CIP2A stabilizes oncogenic proteins such as MYC and Akt, promoting uncontrolled cell proliferation, survival, and malignant transformation.
Overexpression of CIP2A is observed in numerous cancers, including breast, lung, gastric, and hepatocellular carcinomas, and is often correlated with poor prognosis, metastasis, and chemotherapy resistance. Its oncogenic properties are linked to multiple pathways: CIP2A enhances MYC-driven transcription by preventing PP2A-mediated dephosphorylation of MYC at serine 62. a critical modification for MYC protein stability. Additionally, CIP2A activates the PI3K/Akt/mTOR axis, further supporting tumor cell survival and growth.
Recombinant CIP2A protein is widely used in biochemical and functional studies to elucidate its interaction networks, structural features, and therapeutic targeting potential. Researchers employ it to investigate mechanisms of PP2A inhibition, screen small-molecule inhibitors, or validate antibody specificity. Recent studies also explore CIP2A's extracellular roles, suggesting its secretion by cancer cells may influence the tumor microenvironment. As a promising therapeutic target, CIP2A-focused strategies, including gene silencing and targeted degradation, are under preclinical evaluation. Understanding CIP2A's molecular behavior through recombinant protein studies remains pivotal for developing precision oncology interventions.
×
